journal
MENU ▼
Read by QxMD icon Read
search

Translational Lung Cancer Research

journal
https://www.readbyqxmd.com/read/28713684/combination-met-and-egfr-directed-therapy-in-met-overexpressing-non-small-cell-lung-cancers-time-to-move-on-to-better-biomarkers
#1
EDITORIAL
Fernando C Santini, Siddharth Kunte, Alexander Drilon
No abstract text is available yet for this article.
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713683/do-we-really-care-about-incidental-lung-nodules-review-of-atypical-lung-carcinoid-and-a-proposal-for-systematic-patient-follow-up
#2
Henal Motiwala, Itisha Bansal, Pradeep Goyal, Olena Dorokhova, Yogesh Kumar, Thomas D Olsavsky, Albert DiMeo, Nishant Gupta
Atypical lung carcinoids are intermediate-grade neuroendocrine tumors (NETs) with malignant potential. They are often detected incidentally on imaging done for non-related causes, as the patients are frequently asymptomatic. Histopathology is required to confirm the diagnosis with immunohistochemistry (IHC). Due to their indolent nature, these are often diagnosed only in the advanced stages. Treatment options include chemoradiation for widespread disease versus surgery for local or minimally invasive disease...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713682/predictive-biomarkers-of-immunotherapy-for-non-small-cell-lung-cancer-results-from-an-experts-panel-meeting-of-the-italian-association-of-thoracic-oncology
#3
REVIEW
Cesare Gridelli, Andrea Ardizzoni, Massimo Barberis, Federico Cappuzzo, Francesca Casaluce, Romano Danesi, Giancarlo Troncone, Filippo De Marinis
Unleashing the potential of immune system to fight cancer has become one of the main promising treatment modalities for advanced non-small cell lung cancer (NSCLC). The knowledge of numerous factors that come into play in the cancer-immunity cycle provide a wide range of potential therapeutic targets, including monoclonal antibodies that inhibits the programmed death-1 (PD-1) checkpoint pathway. Over the last two years, nivolumab, pembrolizumab and atezolizumab received approval for treatment of pretreated advanced NSCLC, and more recently, immunotherapy with pembrolizumab is the new standard of care as first-line in patients with high levels of programmed death-ligand 1 (PD-L1) expression...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713681/the-use-of-tcp-based-eud-to-rank-and-compare-lung-radiotherapy-plans-in-silico-study-to-evaluate-the-correlation-between-tcp-with-physical-quality-indices
#4
Abdulhamid Chaikh, Jacques Balosso
BACKGROUND: To apply the equivalent uniform dose (EUD) radiobiological model to estimate the tumor control probability (TCP) scores for treatment plans using different radiobiological parameter settings, and to evaluate the correlation between TCP and physical quality indices of the treatment plans. METHODS: Ten radiotherapy treatment plans for lung cancer were generated. The dose distributions were calculated using anisotropic analytical algorithm (AAA). Dose parameters and quality indices derived from dose volume histograms (DVH) for target volumes were evaluated...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713680/targeting-the-epigenome-in-malignant-pleural-mesothelioma
#5
REVIEW
Kaitlin C McLoughlin, Andrew S Kaufman, David S Schrump
Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities. Recent insights regarding epigenetic alterations in MPM provide the preclinical rationale for the evaluation of novel combinatorial regimens targeting the epigenome in these neoplasms.
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713679/targeting-eukaryotic-protein-translation-in-mesothelioma
#6
REVIEW
Robert A Kratzke
The default mechanism for protein translation in eukaryotes involves activation of the eIF4 complex at the 5' end of mRNA. This activity is upregulated in cancers, resulting in the expression of a variety of proteins necessary for the development and maintenance of the neoplastic state. Not surprisingly, mesothelioma demonstrates this same reliance on activation of 5' cap mediated translation. Efforts are ongoing to target and exploit our knowledge of this key molecular switch for cancer therapy. Agents targeting the critical eIF4E cap binding protein, disruption of the eIF4 complex, and exploitation for oncolytic virotherapy are some of the important areas of current research in mesothelioma protein translational research...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713678/drug-development-against-the-hippo-pathway-in-mesothelioma
#7
REVIEW
Gavitt A Woodard, Yi-Lin Yang, Liang You, David M Jablons
Advances in the treatments for malignant pleural mesothelioma (MPM) have been disappointing until recently. Conventional cytotoxic drugs fail in MPM in part because they do not address the cancer stem cell population or stem cell pathways that drive tumor resistance and resurgence following treatment. The Hippo stem cell pathway regulates cell contact inhibition with tumor suppressor genes such as NF2 (Neurofibromatosis 2) upstream controlling YAP (Yes-associated protein 1) oncogenes. NF2 is mutated in 40-50% of all MPM and downstream YAP is constitutively active in greater than 70% of MPM, making the downstream YAP/TEAD (transcriptional enhancer associate domain) complex the ultimate target...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713677/radio-immunotherapy-and-chemo-immunotherapy-as-a-novel-treatment-paradigm-in-malignant-pleural-mesothelioma
#8
REVIEW
Licun Wu, Marc de Perrot
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with poor outcome. Novel radical radiation techniques using intensity modulated radiation therapy (IMRT) have become an important component of therapy in mesothelioma. Immunotherapy also provides new therapeutic options. However, how best to integrate immunotherapy with standard therapy such as radiation, chemotherapy and surgery remains unknown. A change of paradigm from adjuvant normofractionation to induction accelerated hypofractionated hemithoracic radiation could provide a platform to combine immunotherapy due to the potential benefit of short course high dose radiation on the immune system...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713676/immunotherapy-for-malignant-pleural-mesothelioma-current-status-and-future-directions
#9
REVIEW
Jordan Dozier, Hua Zheng, Prasad S Adusumilli
Malignant pleural mesothelioma (MPM) has been marked historically by poor prognosis. Current standard of care for this deadly disease results in sub-optimal improvements in overall survival (OS), which has prompted researchers to explore innovative treatment alternatives. Immunotherapy is an emerging therapeutic modality that harnesses the power of the human immune system. In this review, we summarize the different methods of immunotherapy for malignant pleural mesothelioma. Using ClinicalTrials.gov we searched the terms "immunotherapy" and "immune therapy" combined with "pleural mesothelioma"...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713675/novel-systemic-therapy-against-malignant-pleural-mesothelioma
#10
REVIEW
Michael R Mancuso, Joel W Neal
Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum analog, an anti-metabolite, and sometimes anti-angiogenic therapy, but there is currently no well-established standard therapy for refractory or relapsed disease. This review focuses on efforts to develop improved systemic therapy for the treatment of malignant pleural mesothelioma (MPM) including cytotoxic systemic therapy, a variety of tyrosine kinase inhibitors and their downstream effector pathways, pharmacologic targeting of the epigenome, novel approaches to target proteins expressed on mesothelioma cells (such as mesothelin), arginine depletion therapy, and the emerging role of immunotherapy...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713674/intraoperative-adjuncts-for-malignant-pleural-mesothelioma
#11
REVIEW
Warren Ho Chan, David J Sugarbaker, Bryan M Burt
Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common. Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic therapy (PDT) target micrometastatic disease and aim to improve local control. This review details the most recent studies and trials of HIOC, heated intraoperative PVP-I, and PDT, this aims to provide an update on some of the most promising intraoperative adjuncts for patients with MPM...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713673/intraoperative-near-infrared-imaging-of-mesothelioma
#12
REVIEW
Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal
Though difficult to achieve, complete resection of malignant pleural mesothelioma is paramount to improving patient survival. Surgeons have traditionally been limited to using visual inspection and manual palpation to locate and remove cancerous tissue. However, intraoperative molecular imaging (IMI) is a promising new technology in surgery. Molecular imaging utilizes a fluorescent tracer that selectively accumulates in cancer cells. An imaging device is then used to detect and augment the fluorescent signal emitted from the fluorescent cancer cells...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713672/bap1-a-tumor-suppressor-gene-driving-malignant-mesothelioma
#13
REVIEW
Mitchell Cheung, Joseph R Testa
Like cancer generally, malignant mesothelioma (MM) is a genetic disease at the cellular level. DNA copy number analysis of mesothelioma specimens has revealed a number of recurrent sites of chromosomal loss, including 3p21.1, 9p21.3, and 22q12.2. The key inactivated driver genes located at 9p21.1 and 22q12.2 were discovered two decades ago as being the tumor suppressor loci CDKN2A and NF2, respectively. Only relatively recently was the BAP1 gene determined to be the driver gene at 3p21.1 that is somatically inactivated...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713671/diagnostic-and-prognostic-biomarkers-for-malignant-mesothelioma-an-update
#14
REVIEW
Zhongjian Chen, Giovanni Gaudino, Harvey I Pass, Michele Carbone, Haining Yang
Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of its resistance to current therapies, even if higher survival occurs in patients diagnosed and treated when at stage I of the disease. However, these do not exceed 5% of the total number of cases, due to the inadequacy of the existing biomarkers for early and accurate diagnosis. Therefore, new effective biomarkers are needed for MM detection at earlier stages and to develop tailored therapies...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713670/in-vitro-experimental-models-of-mesothelioma-revisited
#15
REVIEW
Anand Singh, Nathanael Pruett, Chuong D Hoang
Malignant pleural mesothelioma (MPM) is a biologically unusual, highly aggressive cancer that defies current multimodality treatments. Epidemiologic data suggest that this malignancy has not abated despite increasingly strict environmental regulations on asbestos, the putative causative agent for sporadic cases. An incomplete understanding of all the factors mechanistically driving mesothelioma is largely responsible for the current lack of curative treatments. Many approaches have been employed to ascertain the step-by-step molecular events involved in mesothelioma oncogenesis including in vitro, small animal in vivo, and human experimental models; though clearly defined, druggable mechanisms still are elusive...
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28713669/the-promise-of-emerging-developments-and-concepts-in-mesothelioma
#16
Chuong D Hoang
No abstract text is available yet for this article.
June 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28529908/rebuttal-from-professor-helmut-h-popper
#17
EDITORIAL
Helmut H Popper
No abstract text is available yet for this article.
April 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28529907/rebuttal-from-professor-sanja-dacic
#18
EDITORIAL
Sanja Dacic
No abstract text is available yet for this article.
April 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28529906/cons-the-confusing-mucinous-adenocarcinoma-classification
#19
EDITORIAL
Helmut H Popper
No abstract text is available yet for this article.
April 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28529905/pros-the-present-classification-of-mucinous-adenocarcinomas-of-the-lung
#20
EDITORIAL
Sanja Dacic
No abstract text is available yet for this article.
April 2017: Translational Lung Cancer Research
journal
journal
49936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"